Please upgrade your browser.
Several additional angiogenesis inhibitors are expected reach the market in the next five years. Compounds to watch include Pfizer's SU-11248, which has demonstrated efficacy in imatinib-resistant gastrointestinal stromal tumors; Bayer and Onyx Pharmaceuticals BAY-43-9006, which is in Phase III for renal cell carcinoma; and Genentech and Novartis's ranibizumab (Lucentis) for AMD.
Jesse said that his dad fought the disease, but it was a difficult process to be a part of. Kidney cancer occurs roughly twice as often in males as in females, according to Kidney Cancer Association. Fifteen to 25 percent of patients have metastatic disease at the time of their diagnosis, meaning their cancer has spread to other areas of the body.
European regulators on Friday recommended GlaxoSmithKline PLC's kidney cancer drug Votrient for conditional marketing authorization and also backed the wider use of the company's breast cancer drug Tyverb.
His patient, a spunky Italian-American woman in her 60s, was waiting in an exam room down the hall for the answer: Was the experimental drug stopping her deadly skin cancer?
So when all was said and done, what actually was accomplished by the seven-hour gabfest at Blair House?
Van Andel Research Institute (VARI) researchers have found a way to reverse resistance to sunitinib, a treatment that is currently the first line of defense against clear cell renal cell carcinoma (ccRCC), a deadly form of kidney cancer. Most patients who show a positive response to sunitinib develop a resistance to the drug after one year of treatment.
A University of North Carolina at Chapel Hill study has found a drug used to treat advanced kidney cancer can also shrink kidney tumors prior to surgery.
A UCLA study reveals how human genes interact with their environment to boost disease risk. Published in the Feb. 18 online edition of the American Journal of Human Genetics, the findings shed light on why the search for specific gene variants linked to human diseases can only partly explain common disorders.
Some good news regarding cancers: If antiretroviral therapy is able to maintain higher CD4 cell counts, it may reduce the risk of various non-AIDS-related cancersnotably those caused by other infectious diseases, human papillomavirus (HPV), for examplein people living with HIV.
|Powered by NeonCRM|